Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook

Courtesy of Benzinga.

Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook

Canaccord Genuity upgraded shares of Illumina, Inc. (NASDAQ: ILMN) to a Buy following a strong second-quarter beat and an upgrade to the revenue guidance.

The firm noted that Illumina reported second-quarter revenues of $662 million, beating the consensus estimate of $642 million, and adjusted earnings per share of 82cents, also exceeding the Street forecast of 69 cents. Gross margins also exceeded forecast, helped by the revenue beat, partly offset by lower gross margins on initial NovaSeq.

The firm also indicated that HiSeqX consumables increased in the second quarter, thanks to strong utilization of HiSeqX in China and due to liquid biopsy studies. However, HiSeq consumables declined sequentially, as customers worked down their inventory as they prepare for conversion to NovaSeq.

On the outlook, the firm noted that the company raised its 2017 revenue growth guidance to the high end of its earlier outlook of 10–12 percent and reiterated its adjusted earnings per share guidance of $3.60–$3.70.

NovaSeq Going Strong

Analyst Mark Massaro noted that NovaSeq beat the Street forecasts as well as the management’s internal order forecast for the second quarter by 30 percent. Illumina announced NovaSeq in January, which is the company’s newest technology to determine the nucleotide order of a given DNA fragment.

tipranks.png

Massaro expressed surprise at the orders from customers new-to-sequencing and the conversion from benchtop-only customers, who accounted for one-third of Illumina’s 95 orders in the second quarter.

The analyst pointed out that we are only in the third quarter in what he believes to be a three-year major upgrade cycle to the Novaseq, with demand springing from all over the globe.

See also: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Additionally, Canaccord Genuity said we are in the early stages of major waves of cancer growth, ranging from development of companion diagnostics for targeted IO therapies to massive oncology studies.

The firm also sees robust ongoing growth in direct-to-consumer revenue and global population level sequencing projects.

“Shipments to China grew +16% and we believe China is likely to be a double-digit grower for ILMN over the next several years, driven by the Chinese Precision Medicine Initiative,” the firm said.

Raising Estimates, Price Target

The firm raised its 2017 revenue estimate from $2,675 million to $2,685 million and 2018 estimate from $2,990 million to $3,010 million. The firm also increased its adjusted earnings per share estimate for 2018 from $4 to $4.30.

For 2019, the firm initiated revenue guidance of $3,250 million and adjusted earnings per share guidance of $4.90.

Along with the upgrade of rating on the shares from Hold to Buy, Canaccord Genuity also raised its price target from $170 to $215.

At the time of writing, shares of Illumina were up 2.63 percent at $199.58.

Latest Ratings for ILMN

Date Firm Action From To
Aug 2017 Canaccord Genuity Upgrades Hold Buy
Jul 2017 Morgan Stanley Maintains Underweight
Mar 2017 Leerink Swann Upgrades Market Perform Outperform

View More Analyst Ratings for ILMN


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings Long Ideas News Guidance Upgrades Health Care


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!